Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations.

Diabetes care - 1 Feb 2008

Rafiq Meena, Flanagan Sarah E, Patch Ann-Marie, Shields Beverley M, Ellard Sian, Hattersley Andrew T

Abstract excerpt

OBJECTIVE: Neonatal diabetes can result from mutations in the Kir6.2 or sulfonylurea receptor 1 (SUR1) subunits of the ATP-sensitive K(+) channel. Transfer from insulin to oral sulfonylureas in patients with neonatal diabetes due to Kir6.2 mutations is well described, but less is known about changing therapy in patients with SUR1 mutations. We aimed to describe the response to sulfonylurea therapy in patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to C-Peptide
Share to Glycated Hemoglobin

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hypoglycemic Agents

Share to Potassium Channels, Inwardly Rectifying

Share to Receptors, Drug

Share to Sulfonylurea Compounds

Share to Sulfonylurea Receptors

Share to Treatment Failure

Source

Open in PubMed Open full text

Identifiers

PMID: 18025408
DOI: 10.2337/dc07-1785
PMCID: PMC7611807

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations.PMID 18025408Read ↗

Successful transfer to sulfonylureas in KCNJ11 neonatal diabetes is determined by the mutation and duration of diabetes.Semantic proximity Read ↗

Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study.Semantic proximity Read ↗

Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.Semantic proximity Read ↗

Transition from insulin to sulfonylurea in a child with diabetes due to a mutation in KCNJ11 encoding Kir6.2--initial and long-term response to sulfonylurea therapy.Semantic proximity Read ↗

Successful transition from insulin to sulfonylurea, on second attempt, in a 24-year-old female with neonatal diabetes secondary to KCNJ11 gene mutation.Semantic proximity Read ↗

Efficacy and safety of sulfonylurea use in permanent neonatal diabetes due to KCNJ11 gene mutations: 34-month median follow-up.Semantic proximity Read ↗

Early transition from insulin to sulfonylureas in neonatal diabetes and follow-up: Experience from China.Semantic proximity Read ↗

Neonatal Diabetes and the KATP Channel: From Mutation to Therapy.Semantic proximity Read ↗

Successful transfer from insulin to oral sulfonylurea in a 3-year-old girl with a mutation in the KCNJ11 gene.Semantic proximity Read ↗

Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) geneSemantic proximity Read ↗

New uses for old drugs: neonatal diabetes and sulphonylureas.Semantic proximity Read ↗

[Low doses of sulphonyluria as a successful replacement for insulin therapy in a patient with neonatal diabetes due to a mutation of KCNJ11 gene encoding Kir6.2].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.